Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023
VANCOUVER, BC — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present two posters – a clinical poster (#CT149) and a translational research poster… Read More




